MRE-269|MRE269|ctive metabolite of selexipag

Cas No.:	475085-57-5
Chemical Name:	ACT-333679; MRE269; MRE 269; ACT333679; ACT 333679
Synonyms:	ACT-333679; MRE269; MRE 269; ACT333679; ACT 333679
SMILES:	OC(COCCCCN(C(C)C)C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)N=C1)=O
Formula:	C₂₅H₂₉N₃O₃
M.Wt:	419.52
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
In Vivo:	The vasorelaxant effects of MRE-269 on rat small intralobar pulmonary artery (SIPA) and EPA are the same, while the other IP receptor agonists induce less vasodilation in SIPA than in EPA[1]. MRE-269 produces substantial relaxation of rat small pulmonary artery, although its effects are only significant at high concentrations of above 10 μM (pEC50, 4.98±0.22). By contrast, in rat small pulmonary veins, MRE-269 only produces minimal relaxation over the whole concentration range, with only significant relaxation occurring at the two highest doses of MRE-269 of 10 and 100 μM[2].
In Vitro:	MRE-269 induces endothelium-independent vasodilation of rat extralobar pulmonary artery (EPA). MRE-269 or other IP receptor agonists including epoprostenol, iloprost, treprostinil and beraprost increase cAMP levels in hPASMC[1]. MRE-269 induces concentration-dependent vasodilation in LPA(+), LPA(-), and SPA(-)[3].

Cat. No.	Product name	Field of application
DC48172	BAY-6672	BAY-6672 is a potent and selective human Prostaglandin F (FP) receptor antagonist with an IC50 value of 11 nM.
DC10475	Grapiprant	Grapiprant is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2)
DC8348	TG6-10-1	TG6-10-1 is a cell-permeable,highly potent, selective, and competitive antagonist of prostaglandin E2 receptor (EP2, Kb = 17.8 nM).
DC9609	Terutroban	Terutroban is a thromboxane/prostaglandin endoperoxide receptor antagonist.
DC8624	Setipiprant(ACT129968)	Setipiprant is an orally available, selective CRTH2 antagonist. CRTH2 is a G protein-coupled receptor for PGD2.
DC8353	PF-04418948	PF-04418948 is an orally active, potent, and selective EP2 receptor antagonist (IC50 = 16 nM).
DC11043	Omidenepag	Omidenepag is a potent, selective agonist human EP2 receptor with binding IC50/EC50 of 10/1.7 nM, >500-fold selectivity over EP1, EP3 and EP4 receptors; Omidenepag is the active form of Omidenepag Isopropyl (OMDI).
DC10437	MRE-269	MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
DC10785	MK-7246	MK-7246 is a potent and selective CRTH2 antagonist with a Ki of 2.5±0.5 nM.
DC1009	Laropiprant	MK 0524 is a potent, selective DP1 receptor antagonist with Ki values of 0.57 nM and 0.75 µM for the DP1 and DP2 receptors, respectively.